up protherics
22 Aug 2017
Re: Excellent H1 results today GretelI agree great set of results..Its unfortunate that the market doesn't agree.. Clinigen is up yet again.INMO this will be taken over, which is a shame.. The worst scenario is that this will go for 80 pence.. which is now looking more and more likely. Looks like the institutions have already agreed to go with Cliniigen.
gretel
22 Aug 2017
Excellent H1 results today and a strong outlook going forward.With the CEO noting that the strategic review "has progressed more quickly than we envisaged", perhaps Clinigen will have to increase their offer....[link]
up protherics
16 Aug 2017
Looks Like Forms 8.35 have started to be submitted.. Slater being the first.We will get a good idea if this offer succeeds depending on the amount of notifications.Slater 2.18%INMO Clinigen is now contacting shareholders..Even before a formal offer.. Which sounds a little odd to me.. Can anyone shed any light on this.
up protherics
16 Aug 2017
Re: Possible Offer I wouldn't be surprised if the offer falls through.. Clinigen currently has little cash reserves so any offer will be heavily paper based.. I am not sure that the institutions will sell out under those conditions.I bought in after holding Cyprotex and then seeing Harwood invest.. Personally I am very happy and I would recommend anyone to follow his investments.I held Cyprotex for over eight years and was initially disappointed when they were sold just as things seemed to be taking off for them..However I feel I have been compensated investing in this stock..Whatever happens now should be a win win situation. As even if the offer fails we are looking at good solid growth over the next couple of yea
CarlosAlberto70
15 Aug 2017
Up Up and away ? Has some news broken ?or is it just good results imagined.Oh and by the way, no new MAs in July either.
CarlosAlberto70
09 Aug 2017
Re: No new MAs in June A bit of a non-statement I thought this morning.Guess we have to wait until month end to find out the detail.In answer to your question, with the removal of Biodose and NupharmI would expect to see Y/E Ebitda of £ 15m on sales of £ 70m,but we wont know that until April or so next year.Flag firmly nailed to the mast !
up protherics
07 Aug 2017
Re: No new MAs in June According to the last trading update things are going well. The increase in sales from niche and specials should offset any decrease in ebita..For me I will be looking for some sort of progress in them licensing their products overseas either by themselves or through a third party.. Alternatively indicating when further products will be licensed.Lets hope there is nothing hidden in terms of negative news.Do you have any thoughts as to what we can expect underlying profit to be for year end.
CarlosAlberto70
05 Aug 2017
Re: No new MAs in June I am pretty confident we'll see some approvals in the next 6 months but that is very much determined by the speed of the authorities in reviewing the files, and obviously there will be a delay in pushing their way through to the sales line.But at least it builds the asset base.As previously mentioned those new MAs from the backend of 2016 should show up in the top and bottom line next week.Although, one thing I will be looking for is a bit more info on the Biodose sale £ 2m seems very cheap for £ 22m worth of sales, even if it was losing a small amount of money.I hope some liabilities were transferred in the sale as well. I am sure Healthnet will be rubbing their hands if not, as they are much better placed to integrate that business into their current structure and extract significant savings.
up protherics
04 Aug 2017
Re: No new MAs in June CarlosI hope you are right about some action occurring over the next six months as a trading update is imminent.Personally I was expecting a bit more action on the share front.. So in my view there will need to be a very positive update to either push the price forward or hold it at is current level.Either way we should have our answer at the end of next week.
CarlosAlberto70
30 Jul 2017
No new MAs in June In fact no new MAs this year.Last one was Gabapentin soln. in December, which might have been launched last month.Given that their new push of UL2L was only announced in Aug last year, this is not so surprising, as it usually takes 12-18 months to get an MA after submission. And the Lamda guys know what they are doing, as they develop for third parties as well as in house.So we should see some action in the H2 this year.Looking forward to the results in 10 days time.
Carefully Does It
26 Jul 2017
Re: dividend Held CRX to sale and also the CLN's.Hold NAS that covers QP and EKF as a major shareholder in both.They also held SBS and some CRX via Trident.Getting to a point where, even though it costs, it can be easier to let the likes of Chris Mills cover a few for me. I can't keep an eye on a great deal of shares and it helps spread the risk.
up protherics
26 Jul 2017
dividend Does anyone have an idea if this is likely to pay a dividend this year..Revenue should be good.. So hopefully the funds will go to sharehold
up protherics
06 Jul 2017
Cyprotex Are there any ex Cyprotex holders here apart from main investors..Could someone also answer as to why Quantum doesn't form a closer strategic partnership witn Futura Medical . I.E MED2002.. Surely this is a potential blockbuster (not the old video store, but sales wise )
gretel
26 Jun 2017
Excellent RNS today Very good news all round on both current trading and the disposal of Biodose.N+1 Singer say this morning:"Going forward we think the recent re-rating of the company, which is moving steadily from turnaround to growth, should continue, assuming further positive underlying momentum at the update scheduled for 9 August."
up protherics
21 Jun 2017
Spread I would be interested in any ones view re the spread.From what I can gather the stock is traded via sets.. which should be a good thing re the spread and trading level.. However.. The spread seems to be constantly adjusting on little volume.I always understood that sets was supposed to remove this factor????I just hope this is not down to some spread betting firm
